Related Experiment Video
Updated: Jun 3, 2026
11:25
Multi-step Preparation Technique to Recover Multiple Metabolite Compound Classes for In-depth and Informative Metabolomic Analysis
Published on: July 11, 2014
3-Heptanone as a potential new marker for valproic acid therapy
S Erhart1, A Amann, E Haberlandt
1Department of Pediatrics, Neuropediatrics and Inherited Metabolic Disorders, Innsbruck Medical University, Anichstrasse 35, A-6200 Innsbruck, Austria.
Journal of Breath Research
|March 9, 2011
Summary
Patients with epilepsy on valproic acid (VPA) therapy showed elevated 3-heptanone in breath. However, this breath biomarker did not correlate with VPA levels or dosage.
Area of Science:
- Biochemistry
- Analytical Chemistry
- Clinical Neurology
Background:
- Volatile organic compounds (VOCs) in human breath offer insights into physiological states.
- Valproic acid (VPA) is a common antiepileptic drug with known therapeutic and side effects.
- Identifying non-invasive biomarkers for VPA therapy monitoring is clinically relevant.
Purpose of the Study:
- To investigate the concentration of 3-heptanone in the breath of epilepsy patients undergoing valproic acid monotherapy.
- To determine if serum valproic acid concentrations correlate with exhaled 3-heptanone levels.
Main Methods:
- Proton transfer reaction mass spectrometry (PTR-MS) was used to analyze breath gas samples.
- 27 epilepsy patients (17 male, 10 female; mean age 9.7 years) on VPA therapy were included.
- Serum VPA concentrations were measured concurrently with breath analysis.
Main Results:
- All patients exhibited significantly elevated concentrations of 3-heptanone in their exhaled breath (mean 14.7 ppb).
- No significant correlation was found between serum VPA concentrations and 3-heptanone levels in breath.
- The daily dose of valproic acid also did not correlate with the measured 3-heptanone concentrations.
Conclusions:
- Elevated 3-heptanone in breath gas is a potential indicator in patients treated with valproic acid.
- 3-heptanone breath levels do not serve as a reliable biomarker for valproic acid serum concentrations or dosage in this cohort.
- Further research is needed to understand the source and implications of elevated 3-heptanone during VPA therapy.
Related Concept Videos
01:26Therapeutic Drug Monitoring: Drug Analysis Methods
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
01:16Therapeutic Drug Monitoring: Overview and Classification
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
01:20Measurement of Bioavailability: Pharmacodynamic Methods
Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.
01:19Phase I Reactions: Oxidation of Aliphatic and Aromatic Carbon-Containing Systems
Phase I biotransformation reactions are integral to drug metabolism, predominantly involving oxidative, reductive, and hydrolytic transformations. Chief among these are oxidative reactions, which enhance the hydrophilicity of xenobiotics and introduce polar functional groups to facilitate their elimination from the body.
Oxidation reactions are fundamental in aromatic carbon-containing systems. An example is the hydroxylation of phenobarbital, a process that transforms it into...
Oxidation reactions are fundamental in aromatic carbon-containing systems. An example is the hydroxylation of phenobarbital, a process that transforms it into...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...